Home > Treatment Options > Tumor Suppressors > Clinical Trials >

AZD2014 (Vistusertib™)

Last Updated: 08/4/17

chemical compound
Trade Name Vistusertib™
Other Names AZD2014, AZD-2014, AZD 2014,
Pharmaceutical Companies AstraZeneca
NF2 Trial Availability USA 2017
Taken By Pill (oral)
Tumor Target Recurrent Meningioma
NF2 Trials


  • Recruiting Trial: NCT02831257 | Neurofibromatosis 2 (NF2) - Meningioma | Phase 2: July 2016
  • Not Open: NCT03071874 | Multiple Meningioma | Phase 2: April 15, 2017
Inhibitor mammalian Target of Rapamycin (mTOR); Autophagy; mTORC1/mTORC2
Molecular Formula C25H30N6O3

Sources

  1. "AZD2014" National Center for Biotechnology Information. PubChem Compound Database; CID=25262792, https://pubchem.ncbi.nlm.nih.gov/compound/25262792
  2. Mawrin, Christian. "Looking for the needle in the haystack: Proteome-based identification of treatment targets in NF2-related nervous system tumors." EBioMedicine 16 (2017): 6-7.
    Source: http://www.sciencedirect.com/science/article/pii/S2352396417300488| DOI: 10.1016/j.ebiom.2017.01.044


Solubility: Soluble in DMSO, not in water. Dimethyl Sulfoxide (DMSO) is an organosulfur compound with the formula (CH3)2SO.
http://www.medkoo.com/products/4591

Also in Trials for:

  • Conditions
  • Stomach Neoplasms
  • Advanced Cancer
  • Solid Tumor
  • Prostate Cancer
  • Advanced Metastatic Breast Cancer
  • Glioblastoma Multiforme
  • Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
  • Advanced Solid Malignancies
  • Metastatic Clear Cell Renal Carcinoma
  • Meningioma
  • Breast Cancer|Malignant Female
  • Reproductive System Neoplasm
  • Neurofibromatosis 2|Meningioma
  • Triple-Negative Breast Cancer|Squamous Cell Lung Cancer|Non-squamous Cell Lung Cancer With KRAS Mutations|Non-squamous Cell Lung Cancer With Wild-type KRAS